BACKGROUND: Ginsenoside Rg3 is an extract from the natural product ginseng. Previous studies have linked Rg3 with anti-metastasis of cancer in vivo and in vitro. CXC receptor 4 (CXCR4) is a vital molecule in migration and homing of cancer to the docking regions. METHODS: In this study, the effects of Rg3 on CXCR4 expression were investigated in a breast cancer cell line. Immunohistochemistry, chemotaxis and wound healing mobility assays were performed in cultured MDA-MB-231 cells. RESULTS: At a dosage without obvious cytotoxicity, Rg3 treatment elicits a weak CXCR4 stain color, decreases the number of migrated cells in CXCL12-elicited chemotaxis and reduces the width of the scar in wound healing. CONCLUSION: This work suggests that Rg3 is a new CXCR4 inhibitor from a natural product.
BACKGROUND:Ginsenoside Rg3 is an extract from the natural product ginseng. Previous studies have linked Rg3 with anti-metastasis of cancer in vivo and in vitro. CXC receptor 4 (CXCR4) is a vital molecule in migration and homing of cancer to the docking regions. METHODS: In this study, the effects of Rg3 on CXCR4 expression were investigated in a breast cancer cell line. Immunohistochemistry, chemotaxis and wound healing mobility assays were performed in cultured MDA-MB-231 cells. RESULTS: At a dosage without obvious cytotoxicity, Rg3 treatment elicits a weak CXCR4 stain color, decreases the number of migrated cells in CXCL12-elicited chemotaxis and reduces the width of the scar in wound healing. CONCLUSION: This work suggests that Rg3 is a new CXCR4 inhibitor from a natural product.
Authors: Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim Journal: Cancer Res Date: 2004-06-15 Impact factor: 12.701
Authors: Sharon A Williams; Yuka Harata-Lee; Iain Comerford; Robin L Anderson; Mark J Smyth; Shaun R McColl Journal: Mol Cancer Date: 2010-09-17 Impact factor: 27.401
Authors: Maryam Nakhjavani; Helen M Palethorpe; Yoko Tomita; Eric Smith; Timothy J Price; Andrea J Yool; Jinxin V Pei; Amanda R Townsend; Jennifer E Hardingham Journal: Pharmaceuticals (Basel) Date: 2019-08-01